Thymoma
Conditions
Brief summary
Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.
Detailed description
Thymoma is 1 rare type of tumor developed on the thymic epithelium; patients with thymoma also might have myasthenia gravis (MG). Because of the scarcity and complexity of MG-associated thymoma, its pathogenesis and etiology still remain unclear nowadays. The expression of C-X-C chemokine receptor type 4 (CXCR4) is absent or low in most healthy tissues but highly expressed in various types of tumors. CXCR4 might contribute to the clinical cancer progression, and CXCR4 could be a valuable prognostic biomarker in the therapy of MG-associated thymoma.
Interventions
DRUG68Ga-Pentixafor
Intravenous injection of one dosage of 74-185 MBq(2-5 mCi) 68Ga-Pentixafor. Tracer doses of 68Ga- Pentixafor will be used to image lesions of thymoma by PET/CT.
Sponsors
Peking Union Medical College Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* suspected or confirmed untreated thymoma patients * signed written consent.
Exclusion criteria
* pregnancy * breastfeeding * known allergy against Pentixafor * any medical condition that in the opinion of the investigator,may * significantly interfere with study compliance.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SUVmax and SUVmean | through study completion, an average of 1.5 years | SUVsof focal lesions are measured on 68Ga-Pentixafor PET/CT. The SUVs of the blood pool and muscle are defined as the background activity on the condition that there is no focally hypermetabolic disease. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diagnostic value | through study completion, an average of 1.5 years | Diagnostic value of 68Ga-Pentixafor PET/CT for thymoma in comparison with 18F-FDG PET/CT or CT or MRI. |
| Diagnostic value in special type of thymoma | through study completion, an average of 1.5 years | Diagnostic value of 68Ga-Pentixafor PET/CT in special type thymoma (A\\AB\\B\\C subtypes) |
| Diagnostic value in thymoma and other masses | through study completion, an average of 1.5 years | Diagnostic value of 68Ga-Pentixafor PET/CT in thymoma and other anterior mediastinal mass. |
| CXCR4 expression and SUV | through study completion, an average of 1.5 years | Correlation between CXCR4 expression and SUV in PET |
Countries
China
Contacts
Primary ContactRongxi Wang
Backup ContactZhaohui Zhu
Outcome results
None listed